Clinical Trial Update: The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update evaluates the effect of combining mosapride with a DPP-4 inhibitor on plasma incretin hormone levels in patients with Type 2 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• DPP-4 inhibitor
• Mosapride (mosapride)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED